Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT02886585 |
TitlePembrolizumab In Central Nervous System Metastases | 阶段
第二阶段
|
Date Added 2016-09-01 |
地点
Massachusetts, United States
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Pembrolizumab |
标签
MSS/ MMRp
|
| NCT ID NCT03030378 |
Title治疗实体瘤患者的 Pembrolizumab 和重组白细胞介素-12 | 阶段
第 1 阶段
|
Date Added 2017-01-25 |
地点
California, United States
Colorado, United States Connecticut, United States Florida, United States Georgia, United States Iowa, United States Maryland, United States Massachusetts, United States Missouri, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States Texas, United States Virginia, United States |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Edodekin alfa, Pembrolizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05201612 |
TitlePembrolizumab和Olaparib治疗同源重组缺陷（HRD）晚期结直肠癌（CRC）。 | 阶段
第二阶段
|
Date Added 2022-01-21 |
地点
西班牙
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
Unknown status
|
药物
Olaparib, Pembrolizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05333809 |
TitlePembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2022-04-19 |
地点 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物
Disitamab vedotin, Pembrolizumab, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT05491083 |
TitlePembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer | 阶段
第 1 阶段
|
Date Added 2022-08-08 |
地点 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
尚未招聘
|
药物
Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II) |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03844750 |
TitlePembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery | 阶段
第二阶段
|
Date Added 2019-02-18 |
地点
California, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Pembrolizumab, Vactosertib, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT03239145 |
TitlePembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | 阶段
第 1 阶段
|
Date Added 2017-08-03 |
地点
Massachusetts, United States
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Pembrolizumab, Trebananib |
标签
MSS/ MMRp
|
| NCT ID NCT03638297 |
TitlePD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer | 阶段
第二阶段
|
Date Added 2018-08-20 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
PD-1 antibody + cox inhibitor |
标签
MSI-H/ MMRd
|
| NCT ID NCT02215889 |
Title肝脏部分 2/3 移植研究 | 阶段
第 1 阶段
|
Date Added 2014-08-13 |
地点
挪威
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06764680 |
TitleOral Chemotherapy, Targeted Therapy and Immunotherapy With/without Radiotherapy As 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer | 阶段
第二阶段
|
Date Added 2025-01-08 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物 |
标签
MSS/ MMRp
|
